Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone Acetate
18%
Adenocarcinoma
18%
Adverse Event
54%
Androgen
17%
Antitumor Activity
32%
Bevacizumab
39%
Breast Cancer
53%
Carboplatin
46%
Carcinoembryonic Antigen
18%
Castration Resistant Prostate Cancer
24%
Cetuximab
39%
Chemotherapy
95%
Clinical Trial
54%
Combination Therapy
18%
Digestive System Cancer
16%
Diseases
83%
Docetaxel
37%
Doxorubicin
28%
Edrecolomab
19%
Eltrombopag
39%
Epidermal Growth Factor Receptor
17%
Gemcitabine
33%
Ibritumomab Tiuxetan
19%
Idiopathic Thrombocytopenic Purpura
74%
Immunoglobulin
17%
Iodine-131
37%
Malignant Neoplasm
67%
Maximum Tolerated Dose
36%
Metastatic Breast Cancer
28%
Metastatic Colorectal Cancer
26%
Metastatic Melanoma
19%
Monoclonal Antibody
87%
Neoplasm
90%
Neutropenia
19%
Non Small Cell Lung Cancer
48%
Nonhodgkin Lymphoma
66%
Overall Survival
45%
Paclitaxel
33%
Pharmacokinetics
54%
Phase I Trials
80%
Phase II Trials
35%
Placebo
25%
Prednisone
19%
Progression Free Survival
36%
Prostate Cancer
37%
Receptor
25%
Rituximab
42%
Solid Malignant Neoplasm
44%
Subcutaneous Injection
20%
Thrombocytopenia
20%
Medicine and Dentistry
Adverse Event
18%
Antibody-Drug Conjugate
13%
Arm
20%
Arsenic Trioxide
13%
Awareness
28%
B Cell
19%
Bendamustine
13%
Bevacizumab
26%
Breast Cancer
100%
Cancer
21%
Cancer Diagnosis
13%
Carboplatin
13%
CD20
13%
Chemotherapy
11%
Clinical Trial
28%
Clinician
11%
Colorectal Carcinoma
13%
COVID-19
15%
Diagnosis
21%
Diseases
28%
Eltrombopag
33%
Gemcitabine
13%
Glembatumumab Vedotin
13%
Glycoprotein
13%
Idiopathic Thrombocytopenic Purpura
59%
Immunoglobulin
11%
Infusion
11%
Iodine 131
19%
Letrozole
13%
Low and Middle Income Countries
21%
Low Drug Dose
22%
Malignant Neoplasm
42%
Metastatic Colorectal Cancer
19%
Metastatic Melanoma
13%
Monoclonal Antibody
29%
Neoplasm
45%
Non-Hodgkin Lymphoma
23%
Overall Survival
15%
Phase I Trials
13%
Placebo
15%
Platelet
37%
Postmenopause
13%
Prevalence
16%
Progression Free Survival
15%
Quality of Life
14%
Radiation Therapy
13%
Solid Malignant Neoplasm
13%
Tositumomab
13%
Triple Negative Breast Cancer
16%
Veltuzumab
13%
Immunology and Microbiology
Antibody Drug Conjugate
13%
Antibody Response
22%
Antigen Expression
7%
Antiidiotypic Antibody
6%
Arm
22%
B Cell
10%
Biological Product
8%
Blood Level
9%
Blood Plasma
11%
Carcinoembryonic Antigen
13%
CD16
8%
CD20
8%
Chimeric Antibody
8%
Cyclophosphamide
7%
Death Receptor
6%
Edrecolomab
13%
Etaracizumab
6%
Fc Receptor
15%
Glembatumumab Vedotin
13%
Glycoprotein
19%
Human Immunoglobulin
16%
Idiopathic Thrombocytopenic Purpura
33%
Immune Response
29%
Immunity
20%
Immunoglobulin G
7%
Immunoglobulin G1
7%
Immunoglobulin G4
8%
Interferon Type I
13%
Interleukin 2 Receptor
9%
Intravenous Immunoglobulin
25%
Intravenous Immunoglobulin Therapy
6%
Iodine-131
19%
Low Drug Dose
8%
Lupus Erythematosus
7%
Marginal Zone B-Cell
6%
Maximum Tolerated Dose
10%
Monoclonal Antibody
46%
Pharmacokinetics
28%
Plasma Half Life
8%
Platelet
47%
Platelet Count
10%
Prevotella
6%
Rituximab
14%
Somatomedin
6%
T Cell
16%
Thrombocyte Membrane
12%
Tigatuzumab
6%
Trastuzumab
6%
Tumor Antigen
9%
Veltuzumab
6%